Ibsrela

(Tenapanor)

ApprovedSmall molecule

AArdelyx

Ibsrela is one of 55 small molecule programs targeting Constipation. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

HyperphosphatemiaActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

HyperphosphatemiaPhase 3

Active, not recruiting

Irritable Bowel SyndromeApproved

Active, not recruiting

Competition

Competitive Landscape

185 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Lialda

Takeda

Phase 3

2 2

Xifaxan

SSalix

Phase 3

10 3

Zofran

Novartis

Phase 3

1 4

Amitiza

SSucampo Pharma Americas, LLC

Phase 3

5 5

Ibsrela

AArdelyx

Approved

1 6

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 7

Zarontin

PParkedale

Phase 3

1 8

Mesalazine

Ferring

Phase 3

4 9

Saccharomyces Boulardii

BBiocodex

Phase 3

3 10

Trulance

SSalix

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Constipation

NCT06460038

Q2 2027

Phase 3Recruiting

Constipation

NCT07382167

Phase 3Recruiting

Constipation

NCT06810167

Clinical

Trials by Indication[1]

Hyperphosphatemia3 trials

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Completed·AArdelyx·Phase 3·NCT03427125·1,559 enrolled

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Completed·AArdelyx·Phase 3·NCT02675998·219 enrolled

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Completed·AArdelyx·Phase 4·NCT04549597·333 enrolled

Constipation3 trials

Tenapanor in Synucleinopathy-Related Constipation

Recruiting·—·Phase 2·NCT06460038·30 enrolled

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Recruiting·AArdelyx·Phase 3·NCT07382167·692 enrolled

Assessing Tenapanor as a Treatment of CF-related Constipation.

Recruiting·MMassachusetts General Hospital·Phase 3·NCT06810167·25 enrolled

Efficacy and Safety2 trials

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Completed·AArdelyx·Phase 3·NCT02621892·606 enrolled

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

Completed·AArdelyx·Phase 3·NCT02686138·593 enrolled

Dialysis1 trial

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Completed·AArdelyx·Phase 4·NCT03988920·172 enrolled

Treatment1 trial

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

Completed·AArdelyx·Phase 3·NCT02727751·312 enrolled

7 more indications

Safety and Efficacy1 trial

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting·AArdelyx·Phase 3·NCT05643534·180 enrolled

IBS1 trial

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Recruiting·AArdelyx·Phase 2·NCT06553547·72 enrolled

Efficacy1 trial

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Completed·AArdelyx·Phase 2/3·NCT03824587·236 enrolled

Kidney Stone1 trial

A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT06481150·18 enrolled

Pediatric Patients1 trial

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Enrolling by invitation·AArdelyx·Phase 3·NCT05905926·150 enrolled

Irritable Bowel Syndrome1 trial

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

Completed·—·Phase 4·NCT05995899·36 enrolled

Breast1 trial

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Completed·AArdelyx·Phase 1·NCT06203444·7 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 12, 2019

IBSRELA

NDA NDA211801

Oct 17, 2023

XPHOZAH

NDA NDA213931

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Tenapanor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tenapanor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tenapanor. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA213931). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Ibsrela. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Ardelyx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AArdelyx

Patent Landscape[5]

Patent Cliff

Dec 30, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8969377Dec 30, 2029

9408840Dec 30, 2029

12016856Dec 30, 2029

9006281May 2, 2030

8541448Aug 1, 2033

3 more patents

10272079Apr 10, 2034

10940146Apr 10, 2034

12539299Nov 26, 2042

Ibsrela

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Hyperphosphatemia3 trials

Constipation3 trials

Efficacy and Safety2 trials

Dialysis1 trial

Treatment1 trial

Safety and Efficacy1 trial

IBS1 trial

Efficacy1 trial

Kidney Stone1 trial

Pediatric Patients1 trial

Irritable Bowel Syndrome1 trial

Breast1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News